Finanzen von Rallybio Corp (RLYB)RLYBRallybio Corp

Evaluating the bottom line, Rallybio Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 34.52%, provide a clear picture of how effectively RLYB converts its operational activities into shareholder value.

In the context of the broader market, RLYB competes directly with industry leaders such as COYA and RANI. With a market capitalization of $84.41M, it holds a leading position in the sector. When comparing efficiency, RLYB's gross margin of N/A stands against COYA's 100.00% and RANI's 100.00%. Such benchmarking helps identify whether Rallybio Corp is trading at a premium or discount relative to its financial performance.

Rallybio's financial performance shows volatility, with a gross margin of 100% in recent quarters, but it has also reported substantial losses, including a net income loss of $8,278,000 in Q1 2026. The company has a current ratio of 12.92, indicating strong liquidity, but the recent earnings report showed an EPS of -0.48, reflecting ongoing challenges.